Nifty
Sensex
:
:
11332.75
37766.32
-124.15 (-1.08%)
-398.29 (-1.04%)

Pharmaceuticals & Drugs

Rating :
55/99  (View)

BSE: 500124 | NSE: DRREDDY

2780.90
29.60 (1.08%)
25-Mar-2019 | 1:49PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  2744.90
  •  2790.00
  •  2726.75
  •  2751.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  610611
  •  16980.48
  •  2878.00
  •  1872.95

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 45,649.87
  • 25.84
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 50,457.47
  • 0.73%
  • 3.35

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 26.77%
  • 3.31%
  • 8.17%
  • FII
  • DII
  • Others
  • 0.22%
  • 15.74%
  • 45.79%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.54
  • 1.26
  • -2.84

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.00
  • -6.27
  • -8.09

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 0.11
  • -14.21
  • -24.35

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.33
  • 28.40
  • 33.58

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.82
  • 4.38
  • 3.57

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.88
  • 17.53
  • 17.10

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Net Sales
3,864.60
3,834.10
0.80%
3,817.50
3,559.80
7.24%
3,736.50
3,333.20
12.10%
3,553.90
3,611.90
-1.61%
Expenses
3,060.00
3,041.40
0.61%
3,058.20
2,890.40
5.81%
2,967.70
3,010.00
-1.41%
2,990.30
3,021.40
-1.03%
EBITDA
804.60
792.70
1.50%
759.30
669.40
13.43%
768.80
323.20
137.87%
563.60
590.50
-4.56%
EBIDTM
20.82%
20.68%
19.89%
18.80%
20.58%
9.70%
15.86%
16.35%
Other Income
102.30
43.00
137.91%
128.20
31.60
305.70%
50.40
38.00
32.63%
44.90
20.50
119.02%
Interest
24.10
17.20
40.12%
20.80
22.30
-6.73%
19.50
21.50
-9.30%
17.80
19.60
-9.18%
Depreciation
290.30
271.50
6.92%
278.60
270.20
3.11%
278.70
259.20
7.52%
276.30
254.30
8.65%
PBT
592.50
547.00
8.32%
588.10
408.50
43.97%
521.00
80.50
547.20%
314.40
337.10
-6.73%
Tax
101.10
252.80
-60.01%
80.70
112.30
-28.14%
53.20
23.70
124.47%
49.20
9.70
407.22%
PAT
491.40
294.20
67.03%
507.40
296.20
71.30%
467.80
56.80
723.59%
265.20
327.40
-19.00%
PATM
12.72%
7.67%
13.29%
8.32%
12.52%
1.70%
7.46%
9.06%
EPS
30.14
18.26
65.06%
31.22
18.42
69.49%
28.68
4.02
613.43%
16.39
20.36
-19.50%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
14,972.50
14,281.00
14,196.10
15,568.30
15,023.30
13,415.30
11,895.60
9,814.50
7,496.90
6,988.60
6,900.60
Net Sales Growth
4.42%
0.60%
-8.81%
3.63%
11.99%
12.78%
21.20%
30.91%
7.27%
1.28%
 
Cost Of Goods Sold
4,239.10
4,039.50
3,696.50
3,758.50
3,786.40
3,317.10
3,516.80
2,568.30
2,091.10
2,061.70
1,940.40
Gross Profit
10,733.40
10,241.50
10,499.60
11,809.80
11,236.90
10,098.20
8,378.80
7,246.20
5,405.80
4,926.90
4,960.20
GP Margin
71.69%
71.71%
73.96%
75.86%
74.80%
75.27%
70.44%
73.83%
72.11%
70.50%
71.88%
Total Expenditure
12,076.20
11,929.80
11,723.90
11,983.00
11,529.70
10,164.70
9,176.10
7,374.90
5,936.00
5,563.50
5,587.60
Power & Fuel Cost
-
329.30
330.10
315.20
339.10
319.90
335.40
225.90
183.30
141.50
122.70
% Of Sales
-
2.31%
2.33%
2.02%
2.26%
2.38%
2.82%
2.30%
2.45%
2.02%
1.78%
Employee Cost
-
3,214.90
3,106.80
3,117.40
2,944.60
2,475.40
1,928.70
1,591.20
1,304.80
1,183.20
992.00
% Of Sales
-
22.51%
21.88%
20.02%
19.60%
18.45%
16.21%
16.21%
17.40%
16.93%
14.38%
Manufacturing Exp.
-
1,746.50
1,886.60
1,856.40
1,999.10
1,747.60
1,441.30
1,237.00
985.90
921.80
1,115.30
% Of Sales
-
12.23%
13.29%
11.92%
13.31%
13.03%
12.12%
12.60%
13.15%
13.19%
16.16%
General & Admin Exp.
-
1,198.90
1,339.90
1,271.40
1,037.30
1,004.30
796.30
682.90
479.00
413.50
582.30
% Of Sales
-
8.40%
9.44%
8.17%
6.90%
7.49%
6.69%
6.96%
6.39%
5.92%
8.44%
Selling & Distn. Exp.
-
1,330.20
1,293.40
1,181.10
1,357.50
1,264.80
1,119.10
984.40
744.90
691.00
651.30
% Of Sales
-
9.31%
9.11%
7.59%
9.04%
9.43%
9.41%
10.03%
9.94%
9.89%
9.44%
Miscellaneous Exp.
-
70.50
70.60
483.00
65.70
35.60
38.50
85.20
147.00
150.80
651.30
% Of Sales
-
0.49%
0.50%
3.10%
0.44%
0.27%
0.32%
0.87%
1.96%
2.16%
2.66%
EBITDA
2,896.30
2,351.20
2,472.20
3,585.30
3,493.60
3,250.60
2,719.50
2,439.60
1,560.90
1,425.10
1,313.00
EBITDA Margin
19.34%
16.46%
17.41%
23.03%
23.25%
24.23%
22.86%
24.86%
20.82%
20.39%
19.03%
Other Income
325.80
155.20
171.50
295.00
274.10
169.90
149.90
132.30
52.30
103.10
99.40
Interest
82.20
78.80
63.40
82.60
108.20
126.70
100.30
114.10
32.30
38.50
108.20
Depreciation
1,123.90
1,077.20
1,026.60
938.90
759.90
647.50
550.20
518.10
398.10
413.10
497.70
PBT
2,016.00
1,350.40
1,553.70
2,858.80
2,899.60
2,646.30
2,218.90
1,939.70
1,182.80
1,076.60
806.50
Tax
284.20
438.00
296.50
751.10
563.20
683.10
637.90
503.50
183.90
266.80
260.80
Tax Rate
14.10%
32.43%
19.08%
26.27%
19.42%
25.81%
29.47%
27.90%
15.55%
43.15%
-39.74%
PAT
1,731.80
912.40
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
351.50
-917.10
PAT before Minority Interest
1,731.80
912.40
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
351.50
-917.10
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
11.57%
6.39%
8.86%
13.54%
15.55%
14.63%
12.83%
13.25%
13.32%
5.03%
-13.29%
PAT Growth
77.69%
-27.43%
-40.35%
-9.79%
19.01%
28.58%
17.36%
30.23%
184.18%
138.33%
 
Unadjusted EPS
106.43
57.08
77.53
124.93
137.18
115.45
89.93
76.76
59.06
20.83
-54.48

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
12,571.60
12,262.10
12,569.80
9,853.10
7,865.20
6,369.10
4,989.00
4,031.90
3,776.80
3,526.10
Share Capital
83.00
82.90
85.30
85.20
85.10
84.90
84.80
84.60
84.40
84.20
Total Reserves
12,406.00
12,098.80
12,393.90
9,677.40
7,698.60
6,215.30
4,849.10
3,906.80
3,657.40
3,403.00
Non-Current Liabilities
2,538.40
456.10
876.70
1,678.40
2,182.30
1,285.10
1,609.80
600.30
1,491.00
2,051.40
Secured Loans
63.00
59.70
74.70
77.50
94.70
80.20
26.10
24.40
26.90
38.60
Unsecured Loans
2,445.90
485.20
993.80
1,354.00
1,980.80
1,185.70
1,615.80
512.80
1,457.10
1,959.00
Long Term Provisions
81.70
84.20
95.20
77.90
56.30
51.40
33.30
28.80
0.00
0.00
Current Liabilities
6,893.80
8,419.90
6,347.10
6,821.30
5,790.40
5,658.80
4,591.40
4,208.50
2,024.80
1,711.20
Trade Payables
1,334.50
1,056.90
906.80
867.30
893.20
965.70
756.60
634.50
1,667.90
1,505.60
Other Current Liabilities
2,411.40
2,339.70
2,409.10
2,624.40
2,020.80
2,120.40
1,749.20
1,328.90
6.70
6.20
Short Term Borrowings
2,556.20
4,362.60
2,271.80
2,185.70
2,060.70
1,898.60
1,588.80
1,831.90
0.00
0.00
Short Term Provisions
591.70
660.70
759.40
1,143.90
815.70
674.10
496.80
413.20
350.20
199.40
Total Liabilities
22,003.80
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
7,292.60
7,288.70
Net Block
6,968.00
6,930.70
6,563.00
5,377.00
4,640.80
4,050.60
3,411.70
3,385.50
2,352.20
2,927.00
Gross Block
17,436.30
15,932.40
15,019.70
12,573.60
11,917.60
10,089.40
8,842.30
7,975.10
6,446.80
6,502.70
Accumulated Depreciation
10,463.00
9,001.70
8,456.70
7,169.90
7,276.80
5,984.60
5,295.30
4,589.60
4,094.60
2,112.90
Non Current Assets
11,505.40
11,454.40
7,999.60
6,476.10
5,512.20
4,786.30
4,191.20
4,025.70
3,115.00
3,357.20
Capital Work in Progress
3,470.50
3,324.50
772.20
529.00
638.80
565.30
708.50
575.20
762.20
429.60
Non Current Investment
465.30
682.60
329.70
145.60
0.40
0.40
0.90
0.90
0.60
0.60
Long Term Loans & Adv.
564.80
482.10
290.40
418.10
232.20
149.10
70.10
64.10
0.00
0.00
Other Non Current Assets
36.80
34.50
44.30
6.40
0.00
20.90
0.00
0.00
0.00
0.00
Current Assets
10,498.40
9,683.70
11,794.00
11,876.70
10,325.70
8,526.70
6,999.00
4,815.00
4,177.60
3,931.50
Current Investments
1,833.00
1,427.10
3,503.40
2,102.20
1,066.40
196.60
207.00
0.00
357.40
51.70
Inventories
2,908.90
2,852.80
2,557.90
2,569.90
2,418.80
2,170.70
1,943.30
1,599.20
1,339.40
1,325.00
Sundry Debtors
4,052.70
3,798.60
4,125.00
4,101.20
3,325.30
3,180.40
2,536.80
1,761.10
1,159.90
1,440.60
Cash & Bank
263.80
386.50
492.10
1,872.40
2,300.60
2,017.10
1,606.10
575.10
660.00
562.30
Other Current Assets
1,440.00
451.50
393.10
226.20
1,214.60
961.90
705.80
879.60
660.90
551.90
Short Term Loans & Adv.
958.30
767.20
722.50
1,004.80
1,044.20
796.90
611.60
763.20
658.70
551.20
Net Current Assets
3,604.60
1,263.80
5,446.90
5,055.40
4,535.30
2,867.90
2,407.60
606.50
2,152.80
2,220.30
Total Assets
22,003.80
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
7,292.60
7,288.70

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
1,803.00
2,144.40
3,262.60
2,523.50
1,969.70
1,377.90
1,612.60
755.40
1,315.00
599.10
PBT
1,350.40
1,553.70
2,858.80
2,899.60
2,646.30
2,164.70
1,804.40
1,182.80
618.30
-656.30
Adjustment
1,625.30
1,687.30
1,107.70
1,654.00
1,042.70
1,062.80
1,157.40
530.10
1,117.30
2,080.10
Changes in Working Capital
-896.60
-519.60
-2.50
-1,483.70
-1,005.00
-1,294.40
-893.80
-658.70
-137.50
-545.60
Cash after chg. in Working capital
2,079.10
2,721.40
3,964.00
3,069.90
2,684.00
1,933.10
2,068.00
1,054.20
1,598.10
878.20
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-276.10
-577.00
-701.40
-546.40
-714.30
-555.20
-455.40
-298.80
-283.10
-279.10
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,488.30
-1,840.40
-2,039.40
-2,264.70
-1,694.10
-1,446.30
-1,888.40
-898.80
-710.20
-505.00
Net Fixed Assets
-683.20
-1,019.30
-1,892.20
-828.10
-819.60
-530.80
-554.40
-399.90
-602.60
-571.80
Net Investments
-534.60
1,974.20
-1,213.80
-1,055.80
-427.30
98.50
-15.70
93.10
-851.30
226.80
Others
-270.50
-2,795.30
1,066.60
-380.80
-447.20
-1,014.00
-1,318.30
-592.00
743.70
-160.00
Cash from Financing Activity
-444.00
-369.20
-1,700.10
-433.20
-24.20
-156.80
389.10
44.50
-531.70
-265.10
Net Cash Inflow / Outflow
-129.30
-65.20
-476.90
-174.40
251.40
-225.20
113.30
-98.90
73.10
-171.00
Opening Cash & Equivalents
377.80
492.10
539.50
862.40
520.40
736.20
573.00
660.00
562.30
744.70
Closing Cash & Equivalent
254.20
377.80
492.10
582.90
862.40
520.40
736.20
575.10
660.00
562.30

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
752.35
734.72
731.49
572.92
457.33
371.04
290.91
235.90
221.67
207.08
ROA
4.23%
6.14%
11.05%
13.67%
13.47%
12.46%
12.99%
12.38%
4.82%
-12.24%
ROE
7.40%
10.20%
18.95%
26.63%
27.88%
27.18%
29.15%
25.83%
9.72%
-23.07%
ROCE
8.21%
9.77%
19.55%
22.69%
24.77%
24.79%
26.24%
20.84%
12.18%
-9.14%
Fixed Asset Turnover
0.86
0.92
1.13
1.23
1.23
1.26
1.17
1.04
1.09
1.16
Receivable days
100.33
101.86
96.43
89.72
87.97
87.19
79.59
70.77
67.20
55.01
Inventory Days
73.63
69.56
60.11
60.27
62.06
62.74
65.60
71.20
68.85
63.79
Payable days
37.10
31.00
28.67
28.48
33.96
34.99
35.37
72.19
108.29
85.61
Cash Conversion Cycle
136.86
140.42
127.87
121.51
116.06
114.93
109.82
69.78
27.76
33.19
Total Debt/Equity
0.41
0.40
0.27
0.44
0.58
0.58
0.66
0.59
0.40
0.57
Interest Cover
18.14
25.51
35.61
27.80
21.89
22.58
16.81
37.62
17.06
-5.07

News Update


  • USFDA completes audit at Dr. Reddy's subsidiary in Hyderabad
    23rd Mar 2019, 09:34 AM

    No FDA 483 was issued at the end of inspection

    Read More
  • Dr. Reddy's Laboratories launches B2B customer service portal ‘XCEED’
    19th Mar 2019, 09:55 AM

    The portal is focused on meeting the growing demand for the company’s portfolio of generic APIs

    Read More
  • USFDA completes audit at Dr. Reddy's Louisiana Plant
    22nd Feb 2019, 12:37 PM

    The USFDA has completed audit with one observation

    Read More
  • Dr Reddy's Laboratories recalls 2,770 bags of epilepsy injection in US
    22nd Feb 2019, 09:25 AM

    The reason for recall is the pre-printed text on the primary infusion bag and NDC incorrectly identifies the product as Levetiracetam in 0.75 percent Sodium Chloride

    Read More
  • Dr. Reddy's Lab re-launches Buprenorphine and Naloxone Sublingual Film
    21st Feb 2019, 09:02 AM

    The re-launch comes on the heels of a favorable decision issued by the United States Court of Appeals for the Federal Circuit

    Read More
  • Dr. Reddy's Lab gets EIR for formulations facility in Visakhapatnam
    18th Feb 2019, 09:38 AM

    The company has received EIR from USFDA for FTO VII

    Read More
  • Dr. Reddy's launches Tadalafil tablets in US market
    12th Feb 2019, 11:15 AM

    The company’s Tadalafil Tablets are available in 20 mg with 60 count bottle size

    Read More
  • United Healthcare Services files complaint against Dr Reddy's US subsidiary
    7th Feb 2019, 09:39 AM

    United Healthcare Services has filed a complaint against Dr Reddy's Laboratories and 42 other defendants

    Read More
  • Dr. Reddy's Laboratories’ arm continues to recall Levetiracetam Injection from US market
    6th Feb 2019, 10:57 AM

    The recall, which began in October 2018, was originally initiated due to a product complaint received for mislabelling

    Read More
  • Dr. Reddys Laboratories reports 65% rise in Q3 consolidated net profit
    1st Feb 2019, 15:25 PM

    Total income of the company increased by 2.32% at Rs 3,966.90 crore for Q3FY19

    Read More
  • Dr. Reddys Lab - Quarterly Results
    1st Feb 2019, 14:49 PM

    Read More
  • USFDA completes audit at Dr. Reddy's API manufacturing plant
    28th Jan 2019, 15:05 PM

    The company has been issued with one observation

    Read More
  • Dr. Reddy's Lab, Promius Pharma receive USFDA’s approval for TOSYMRA
    28th Jan 2019, 09:17 AM

    TOSYMRA is indicated for the acute treatment of migraine with or without aura in adults

    Read More
  • Dr. Reddy's launches Propofol Injectable Emulsion in US market
    24th Jan 2019, 11:57 AM

    The company's Propofol Injectable Emulsion, USP is available in 10 mg/ml vials for single patient use only

    Read More
  • USFDA completes inspection at Dr. Reddy's Srikakulum Plant
    16th Jan 2019, 09:07 AM

    The company has been issued a Form 483 with 4 observations

    Read More
  • Dr. Reddy's launches Sevelamer Carbonate for Oral Suspension in US Market
    27th Dec 2018, 11:39 AM

    Dr. Reddy's Sevelamer Carbonate for Oral Suspension is available in 0.8 g and 2.4 g packets in count size of 90

    Read More
  • Dr. Reddy's launches Aspirin, Dipyridamole Capsules in US Market
    24th Dec 2018, 11:18 AM

    Dr. Reddy's Aspirin and Extended-Release Dipyridamole Capsules is available in 25 mg/200 mg strength with 60 count bottle size

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.